The Box 2.0: Using Smart Technology for Early Diagnosis of Complications After Cardiovascular Surgery

September 7, 2021 updated by: RoderickTreskes, Leiden University Medical Center
The objective of this study is to determine the effect on quality of care when introducing smart technology in patients who underwent cardiovascular surgery. Patients who consent to take part in the study, receive a box containing two smartphone compatible ECG monitors, an oxygen saturation monitor, a weight scale, a thermometer, an activity tracker and a blood pressure monitor. They will be followed up by replacing one of the outpatient clinic visits by an e-consult, in which a patients does not have to go to the hospital. Instead, he or she will talk with his or her doctor or nurse practitioner via a secured video connection. The primary endpoint of the study will be the diagnosis of atrial fibrillation within 3 months after cardiac surgery.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Over the past five years, smartphone compatible detectors of cardiovascular disease parameters have been released on the consumers market. Examples of these include heart rate monitors, ECG monitors, blood pressure monitors, activity trackers and fat percentages monitors. These monitors have often been validated and are CE-marked for use in the European Union within their intended use.

Recent publications implicate that home monitoring with such consumer devices might improve quality of care. A study by Bosworth et al. in patients with hypertension showed that increased monitoring and subsequent treatment led to a better controlled blood pressure in patients who were treated for hypertension. Another study, which is currently being carried out at the LUMC, is investigating whether patients benefit from a smart technology intervention after they had a myocardial infarction. Preliminary (unpublished) results show that clinical outcomes are similar, with higher patient satisfaction. Cost analyses show that there is a cost reduction per patient with smart technology follow-up. Therefore, smart technology could be a useful tool to improve patient monitoring and therefore patient safety.

Patients who are discharged after they underwent cardiovascular surgery are at risk to develop one or more of three most seen late complications: sternal wound infection, cardiac decompensation or rhythm disturbances such as atrial fibrillation. This is not always detected before those patients are discharged.

Currently, patients who underwent cardiovascular surgery return to the outpatient clinic 14 days and three months after discharge. They are seen by a specialist nurse or cardiologist, who will perform a general check-up and inspect the sternal wound. An echocardiogram will be performed before the three-month visit. If there is suspicion for a rhythm disturbance on the outpatient clinic visit, the cardiologist might decide to perform Holter monitoring during 24 hours. As this is a small window of time, not all rhythm disturbances will be diagnosed. Smart technology is hypothesized to increase the chances of diagnosing rhythm disturbances. In the case of sternal wound infection and cardiac decompensation, smart technology may show a declining trend before a patient visits the outpatient clinic, which can lead to early detection and treatment.

A small pilot study by McElroy et all found that after cardiovascular surgery, both the patient as well as the health care team are highly satisfied with added smart technology, due to the ease of use of the technology and platform. There was a main focus on readmission rates, which did not differ between the groups. However the trend shows an increase in diagnosing atrial fibrillation (15,4 vs 29,6%), sternal wound infection or cardiac decompensation were not studied.

To our knowledge, no other study has yet looked into diagnosing late complications after cardiovascular surgery with the help of smart technology. It is hypothesized that smart technology could help diagnose the main three diagnoses mentioned above early on and with that, improve quality of care in patients after cardiovascular surgery. Therefore, in this study, the clinical effectiveness of a smart technology intervention is investigated in patients who have underwent cardiovascular surgery at the department of Thoracic Surgery at Leiden University Medical Center.

Study Type

Interventional

Enrollment (Actual)

730

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Zuid Holland
      • Leiden, Zuid Holland, Netherlands, 2333 ZA
        • Leiden University Medical Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient undergoes cardiovascular surgery: CABG, valve reconstruction or replacement, aortic root or ascending aortic surgery, or any other cardiothoracic surgery performed by median sternotomy such as atrial or ventricular septal defect closure, Dor or Morrow procedure, cardiac tumor removal and/or surgical treatment of coronary artery anomalies.
  • Patient is able to communicate in English or Dutch
  • Patient has been referred by a cardiologist from the Leiden University Medical Center, Cardiological Center Voorschoten, Alrijne Hospital or Haaglanden Medical Center

Exclusion Criteria:

  • Patient is < 18 years old
  • Patient is pregnant
  • Patient is considered an incapacitated adult
  • Patient is unwilling to sign the informed consent form
  • Patient undergoes emergency thoracic surgery (INTERMACS 1 or 2)
  • Patient has active endocarditis at the time of operation
  • Patient is on mechanical circulatory support before operation
  • Patient has a ventricular septal rupture
  • Patient undergoes extracorporeal membrane oxygenation or ventricular assist device insertion

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: DIAGNOSTIC
  • Allocation: NON_RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: The Box 2.0
Patients will be given a Box, in which they will find a thermometer, blood pressure monitor, activity tracker, weight scale, blood oxygen saturation monitor, a single lead ECG device and a four lead ECG device. Also, they will be followed-up by use of two webcam consultations instead of a normal outpatient clinic visit.
Patients in the intervention arm will receive a Box with several devices that is hypothesized to allow for better and earlier detection of complications after cardiac surgery.
NO_INTERVENTION: Controls
Patients will not receive a Box. They will be followed up by standard care, returning to the outpatient clinic at the same frequency and timing as The Box 2.0 arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dectection of and time to detection of atrial fibrillation
Time Frame: Until 3 months after surgery
Diagnosis of atrial fibrillation and the time it took a subject to reach that outcome, measured in both study arms
Until 3 months after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dectection of and time to detection of cardiac decompensation
Time Frame: Until 3 months after surgery
Diagnosis of cardiac decompensation and the time it took a subject to reach that outcome, measured in both study arms
Until 3 months after surgery
Quality of Life (QoL)
Time Frame: 3 months after surgery
QoL of both study arms, using the EQ-5D-5L (Dutch translation)
3 months after surgery
Patient satisfaction of care
Time Frame: 3 months after surgery
Satisfaction in both study arms, using a modified PSQ-18 (Dutch translation)
3 months after surgery
Overall mortality
Time Frame: 3 months after surgery
Mortality in both study arms
3 months after surgery
Major adverse cardiac events
Time Frame: Until 3 months after surgery
Either cardiac death, myocardial infarction, cardiac tamponade, TIA or ischaemic stroke
Until 3 months after surgery
Re-admission to either the cardiology or thoracic surgery ward
Time Frame: Until 3 months after surgery
Re-admission in both study arms
Until 3 months after surgery
Total amount of cardiology related visits to an emergency department until three months after discharge
Time Frame: Until 3 months after surgery
ER visits (at the Leids University Medical Center, Alrijne Ziekenhuis or Haaglanden Medisch Centrum) in both arms
Until 3 months after surgery
Blood pressure control
Time Frame: 3 months after surgery
BP control in both study arms, both systolic and diastolic
3 months after surgery
Cost-effectiveness
Time Frame: 2 years
Cost-effectiveness of the intervention
2 years
Detection of and time to detection of sternal wound infection
Time Frame: Until 3 months after surgery
Diagnosis of sternal wound infection and the time it took a subject to reach that outcome, measured in both study arms
Until 3 months after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 2, 2018

Primary Completion (ACTUAL)

March 15, 2021

Study Completion (ACTUAL)

June 15, 2021

Study Registration Dates

First Submitted

September 24, 2018

First Submitted That Met QC Criteria

September 27, 2018

First Posted (ACTUAL)

October 1, 2018

Study Record Updates

Last Update Posted (ACTUAL)

September 8, 2021

Last Update Submitted That Met QC Criteria

September 7, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • NL65959.058.18

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mobile Health

Clinical Trials on The Box 2.0

3
Subscribe